Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have received a consensus rating of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have covered the stock in the last year is $19.00.

Several equities analysts have weighed in on CATX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday, June 25th. B. Riley boosted their target price on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Lifesci Capital restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Perspective Therapeutics in a report on Friday, June 14th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a report on Tuesday, June 18th.

Insiders Place Their Bets

In other news, CFO Jonathan Robert Hunt purchased 2,500 shares of the company’s stock in a transaction dated Friday, May 31st. The stock was bought at an average cost of $14.00 per share, for a total transaction of $35,000.00. Following the purchase, the chief financial officer now owns 34,171 shares of the company’s stock, valued at $478,394. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Jonathan Robert Hunt acquired 2,500 shares of the stock in a transaction dated Friday, May 31st. The stock was bought at an average price of $14.00 per share, for a total transaction of $35,000.00. Following the purchase, the chief financial officer now directly owns 34,171 shares of the company’s stock, valued at approximately $478,394. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Johan M. Spoor acquired 10,000 shares of Perspective Therapeutics stock in a transaction on Thursday, June 13th. The stock was purchased at an average cost of $11.70 per share, with a total value of $117,000.00. Following the purchase, the chief executive officer now directly owns 13,757 shares of the company’s stock, valued at approximately $160,956.90. The disclosure for this purchase can be found here. Insiders acquired 30,814 shares of company stock worth $385,487 in the last quarter. 3.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Perspective Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC purchased a new position in Perspective Therapeutics in the first quarter worth $15,511,000. Affinity Asset Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $6,069,000. Vanguard Group Inc. increased its stake in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. HighTower Advisors LLC bought a new position in Perspective Therapeutics in the 3rd quarter worth $314,000. Finally, Virtu Financial LLC bought a new stake in shares of Perspective Therapeutics during the 1st quarter valued at $138,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 6.3 %

CATX opened at $10.49 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.98 and a current ratio of 12.98. Perspective Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $0.33 million for the quarter. Analysts expect that Perspective Therapeutics will post -1.01 earnings per share for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.